Title
The impact of ERα action on muscle metabolism and insulin sensitivity - Strong enough for a man, made for a woman.

Permalink
https://escholarship.org/uc/item/61r3679r

Authors
Hevener, Andrea L
Zhou, Zhenqi
Moore, Timothy M
et al.

Publication Date
2018-09-01

DOI
10.1016/j.molmet.2018.06.013

Peer reviewed
The impact of ERα action on muscle metabolism and insulin sensitivity — Strong enough for a man, made for a woman

Andrea L. Hevener*, Zhenqi Zhou, Timothy M. Moore, Brian G. Drew, Vicent Ribas

ABSTRACT

Background: The incidence of chronic disease is elevated in women after menopause. Natural variation in muscle expression of the estrogen receptor (ERα) is inversely associated with plasma insulin and adiposity. Moreover, reduced muscle ERα expression levels are observed in women and animals presenting clinical features of the metabolic syndrome (MetSyn). Considering that metabolic dysfunction impacts nearly a quarter of the U.S. adult population and elevates chronic disease risk including type 2 diabetes, heart disease, and certain cancers, treatment strategies to combat metabolic dysfunction and associated pathologies are desperately needed.

Scope of the review: This review will provide evidence supporting a critical and protective role for skeletal muscle ERα in the regulation of metabolic homeostasis and insulin sensitivity, and propose novel ERα targets involved in the maintenance of metabolic health.

Major conclusions: Studies identifying ERα-regulated pathways essential for disease prevention will lay the important foundation for the rational design of novel therapeutics to improve the metabolic health of women while limiting secondary complications that have plagued traditional hormone replacement interventions.

Keywords: Estrogen action; Estrogen receptors; Insulin sensitivity; Metabolic homeostasis

1. INTRODUCTION

For over two decades researchers have shown strong relationships between estrogen action and metabolic health in women. Moreover, epidemiological reports indicate that chronic disease incidence increases in women following menopause. Considering that menopause occurs on average by age 51 (National Institutes of Health, NIA www.nia.nih.gov), and that life expectancy has increased for white females to ~80.6 years (The National Vital Statistics Report, 2012), women in the modern era are challenged with heightened disease risk associated with increasing adiposity and metabolic dysfunction for up to three decades of life. Although many researchers and clinicians have focused on the impact of replacement estrogens to ameliorate clinical features of the metabolic syndrome (MetSyn), considering that estrogen action in this tissue.

Regarding the benefits of exogenous hormone replacement therapy (HRT) on diabetes risk after menopause, large randomized clinical trials of postmenopausal estrogen-based HRT compared with placebo [7]. The mechanism by which HRT reduces T2D incidence in postmenopausal women is not yet known however molecular studies in rodents indicate that this protective effect may be achieved in part as a consequence of estrogen-induced insulin-sensitization. Considering that 75—85% of insulin-stimulated glucose disposal is into skeletal muscle and since skeletal muscle typically represents 30—40% of total body mass, we have focused our efforts in understanding the effects of estradiol/ERα action in this tissue.

In this review, we will present studies related to the biological actions of estrogen receptors in skeletal muscle in controlling glucose homeostasis and insulin sensitivity, as estrogen resistance and metabolic dysfunction are identified as major underpinnings involved in the pathology of chronic diseases that plague our society today. We will present basic research suggesting that the estrogen receptor (ER) α form ERα (encoded by the gene ESR1) is an important target to combat metabolic dysfunction.

2. ER LIGAND-MEDIATED EFFECTS ON METABOLISM AND INSULIN ACTION

Identification and phylogenetic analysis of steroid receptors in basal vertebrates and reconstruction of the sequences and functional attributes of ancestral proteins led to the conclusion that the first steroid

Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA

*Corresponding author. Division of Endocrinology, Diabetes and Hypertension, UCLA David Geffen School of Medicine, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA, 90095-7073. Fax: +310 794 7654. E-mail: ahevenen@mednet.ucla.edu (A.L. Hevener).

Received May 4, 2018 • Revision received June 16, 2018 • Accepted June 18, 2018 • Available online 21 June 2018

https://doi.org/10.1016/j.molmet.2018.06.013
receptor was an estrogen receptor [8]. Early studies in reproductive tissues investigating the actions of estradiol led to the paradigm of classical nuclear ERs as ligand-activated transcription factors [9]. Although ERs exist in two main forms, α and β, which have multiple splice variants of unknown function, ERs exhibit tissue specificity in expression and function [10]. The classical, or genomic mechanism of ER action, describes a scenario whereby the ligand-activated ER dissociates from its chaperone and binds as a dimer either directly to estrogen response elements (ERE) in target genes promoters or indirectly to AP-1 or SP-1 response elements through protein tethering association with other DNA-bound transcription factors [11,12] (Figure 1). Following DNA binding, ER dimers interact with basal transcription factors leading to activation or repression of target gene expression. Overlap in binding sites for E2-ligated ERα and ERβ is observed when receptors are expressed individually; however, when both ERs are present, few sites are shared. Each ER restricts the binding site occupancy of the other, with ERα typically dominating [13]. Moreover, ligand-activated ERs promote transcription in a cyclic fashion. The repeated cycling of the receptor complex on and off target promoters in the presence of continuous E2 stimulation may represent a mechanism of continuous sensing and adaptation to the external hormonal milieu to yield the appropriate transcriptional response [14].

In addition to classical signaling, E2-ERα can act within seconds to minutes via extranuclear and membrane-associated forms of the receptor [15] (Figure 1). Membrane associated receptors localize to caveolae where they congregate with other signaling molecules, including G proteins, growth factor receptors, tyrosine kinases (Src), linker proteins (MNAR), and orphan G-protein coupled receptors (GPCRs) [16]. In a variety of cell types, membrane and extranuclear pools of ERs activate protein kinases that phosphorylate transcription factors to promote their nuclear translocation and transcriptional action [15,17]. The G protein-coupled estrogen receptor (GPER), or GPR30, has been reported to respond to E2; however, its role as an ER is still controversial. Although emerging evidence in murine muscle cells shows diverse distribution of GPR30 in the nucleus, mitochondria, and cytoplasm [18], functional aspects of this receptor in vivo remain unclear; thus, GPR30 will not be discussed in this review.

Although ERs are believed to function almost exclusively as classical nuclear ligand-activated transcription factors with respect to their reproductive actions, the role of nuclear vs. extranuclear actions of ERs in the regulation of metabolism and insulin action remains controversial and inadequately interrogated [19]. More recently, an emerging theme in the field is that for many targets, nuclear and non-nuclear signaling must collaborate to achieve the full biological action of estradiol [20]. Although non-genomic signaling is supported for specific cell types under defined conditions, scientific dissection of these pathways remains challenging, thus a central question in the field pertaining to the tissue-specific sites of action and the molecular mechanisms by which ERα selectively activates or represses target genes remains.

Reduced whole body ERα expression or impaired ERα function due to genetic alteration (including genetic variants) has been linked with increased prevalence of specific features of the metabolic syndrome including insulin resistance and obesity in both male and female human subjects and rodents [21–28]. Since obesity is a prominent phenotype observed in estrogen or ERα deficient rodent models, the specific role of ERα in adipocytes and the phenotypic outcomes of obesity as a consequence of adipose-specific ERα deletion in mice is currently under investigation by several laboratories around the world. Whether the obesity phenotype observed in whole body Esr1+/− mice or women harboring an ESR1 polymorphisms is explained by impaired ERα action in adipose tissue specifically, or as a secondary phenotype of ERα impairment in other metabolic tissues requires resolution.

Insulin resistance is a central disorder in the pathogenesis of obesity and type 2 diabetes and is a defining feature of the Metabolic Syndrome, a clustering of metabolic abnormalities including obesity, hypertension, glucose intolerance, and dyslipidemia [29,30]. Metabolic dysfunction and a clustering of these abnormalities is worrisome as this clinical distinction is now thought to impact nearly a quarter of the US population and drive increased risk of numerous chronic disease states including diabetes, cardiovascular disease, neurodegeneration, and certain forms of cancer [31,32]. Normally cycling pre-menopausal women show enhanced insulin sensitivity compared to men when sensitivity is normalized to lean mass (since women have a reduced

---

**Estrogen Receptor Action**

*Target Gene Regulation*

- **Classical Mechanism**
  
  \[ E_2-ER \text{ complex binds directly to estrogen response elements (ERE)s in target gene promoters.} \]
  
- **Indirect DNA Binding Mechanism—ERE independent Genomic Action**
  
  Protein-protein interactions with other transcription factors (e.g. NFκB, AP1, Runx).

- **Ligand-Independent Genomic Action**
  
  Growth Factors activate Protein Kinase Cascades leading to phosphorylation (P) of ER at EREs.

- **Non-Genomic Mechanism**
  
  Membrane-associated ERs mediate estrogen actions (e.g. G-protein coupled receptors).

---

Figure 1: Molecular actions of ERα to activate or repress target genes by classical DNA binding, non ERE genomic action, or non-genomic actions. ERE, Estrogen response element in target gene promoters; P, phosphorylation; TF, transcription factor.
lean body mass compared to men) [33]. Improved insulin sensitivity and protection against factors promoting insulin resistance are likely underpinnings of reduced type 2 diabetes incidence observed for premenopausal women compared with men [33,34]. Case-in-point, although a 40–50% reduction in insulin-mediated glucose disposal is consistently observed in males following high fat feeding [35,36], E2-replete females, humans and rodents, are typically protected against a high fat diet and acute fatty acid-induced insulin resistance [37,38]. In contrast to the metabolic protection seen in normally cycling premenopausal women, following menopause (biological or surgically-induced), a precipitous decline in insulin sensitivity coincides with a dramatic increase in fat mass, and elevated circulating inflammatory markers, LDL, triglycerides, and fatty acids [176]. Similar to humans, ovariectomy (OVX) mice and rats become insulin resistant, show impaired exercise-stimulated glucose disposal into muscle [39], and are more susceptible to the deleterious effects of high fat diet or lipid oversupply. The physiological consequences of OVX are prevented by treatment with an ERα-specific agonist or by restoration of circulating estradiol within a physiological concentration [40–42]. Although chronic administration of E2 is shown to improve insulin sensitivity in rodents, the acute action of E2 to promote insulin-stimulated glucose uptake into muscle remains disputed; this despite consistent observations of E2-induced activation of Akt and AMP-activated Protein Kinase (AMPK) [42,43]. Furthermore, although administration of intravenous conjugated estrogens and E2 to postmenopausal women or OVX rats, respectively, elicited a significant increase in glucose disposal during hyperinsulinemic-euglycemic clamp studies [44,45], ex vivo treatment of skeletal muscle with E2 failed to recapitulate the same increase in insulin-stimulated glucose disposal [43]. It could be that methodological issues have clouded this relationship since only super-physiological insulin concentrations have been tested thus far, potentially masking the true effects of estradiol on insulin action at physiological insulin doses. This ex vivo observation by Rogers et al. [43] is also in contrast to short-term estradiol effects on insulin action in myotubes from postmenopausal women and age-matched men [46]. Additionally, recent research by Park et al. shows that the timing of E2 administration following menopause may also be of importance given the reduced nuclear expression of ERα found in muscle from women >10 years from final menstrual period (FMP) late postmenopausal (LPM), versus early postmenopausal (EPM) women <6 years from FMP (EPM). Moreover, in parallel with a lack of E2 effect to improve insulin sensitivity in LPM, E2 failed to increase the phosphorylation of AMPK and induce Pgc1α expression unlike EPM [44,47]. Collectively, these data suggest that there could be a critical window of therapeutic opportunity in which E2 administration could be utilized for improving metabolic health and that the expression and functionality of ERα may be a key determinant of therapeutic efficacy [44,47]. Similar to findings for ovarian failure in women and rodents, a reduction in circulating estrogens resulting from rare inactivating mutations of the Cyp19 (aromatase) or experimental deletion in Cyp19 in mice confers an obesity-insulin resistance phenotype [21,48–55]. The physiological and genetic evidence argues that E2 and ER favor insulin sensitivity in rodents and humans of both sexes when E2 is maintained within a tight physiological concentration. Indeed, replacement or augmentation of E2 to supraphysiological levels or over-stimulation of ERs is thought to induce insulin resistance secondary to hyperinsulinemia and or a reduction in total GLUT4 expression in muscle [56,57]. In fact, two studies have reported that in postmenopausal women, higher plasma levels of E2 were prospectively associated with increased risk of developing T2D [58,59]. Clearly, additional studies in rodents and humans using a dose response strategy are necessary to better understand the interplay of steroid hormones including E2, testosterone and progesterone on the regulation of metabolism and insulin action in glucoregulatory tissues. Thus, many questions remain: does E2 enhance skeletal muscle insulin sensitivity and at what minimal pharmacological dose, and what are the critical tissues of E2 action that confer protection against nutrient-induced insulin resistance?

3. ESTROGEN RECEPTOR α — STRUCTURE AND GENOMIC ACTION

The cellular effects of estrogens are mediated by two ERs: ERα (the gene that encodes ERαz) and ERα2 (ERαβ). ERα was identified in 1958 [60], and ERα2 was first identified in the rat prostate and ovary in 1996 [61]. Although splice variants of each receptor have been identified and each exhibit distinct tissue expression patterns and functions [10,62]. With the exception of the ERαzD3 isoform, all other ERs are composed of six functional domains, from A to F, containing an NH2-terminal domain (NTD), DNA-binding domain (DBD), and COOH-terminal ligand-binding domain (LBD) (Figure 2). Two regions, named activation function (AF) have been identified as crucial for the transcriptional response of the ERs; the first is localized at the NTD, and the second is in the LBD [63]. ERα1 and ERα2 are structurally different in the ligand binding pockets, and this knowledge was responsible for driving the development of receptor-specific selective ligands [62], since ERs primarily act as ligand-mediated transcriptional factors [9,62,64,65]. Although ERs were the first of the nuclear superfamily to be cloned over two decades ago [66], the tissue-specific gene targets and mechanisms of action, including activation and repression of genes involved in the integrative regulation of metabolic health, remains an area of intense investigation.

Since ERα is a ligand-dependent transcription factor that regulates a large number of genes in diverse target tissues to achieve selective action, the question arises as to how ERα exerts such specific and exacting control over so many different processes. The interplay between ligand, receptor, DNA sequence, cofactors, chromatin context, and post-translational modifications collectively govern transcriptional regulation by ERα. As stated above, ERα can bind directly to DNA (classical pathway) or can impact gene transcription indirectly via protein–protein tethering. In the classical sense, ERα homodimers are thought to bind specific sequence motifs called estrogen response elements (ERE) (Figure 2). The ERE is a 15bp palindrome consisting of two PuGGA half site separated by a 3bp spacer [67–69]. However, in contrast to the estrogen receptor α, estrogen receptor β (ERβ) lacks a classical ERE motif [69]. The last 6 bases of the ERα motif are often referred to as the infla motif [69]. The physiological and genetic evidence argues that E2 and ER favor insulin sensitivity in rodents and humans of both sexes when E2 is maintained within a tight physiological concentration. Indeed, replacement or augmentation of E2 to supraphysiological levels or over-stimulation of ERs is thought to induce insulin resistance secondary to hyperinsulinemia and or a reduction in total GLUT4 expression in muscle [56,57]. In fact, two studies have reported that in postmenopausal women, higher plasma levels of E2 were prospectively associated with increased risk of developing T2D [58,59]. Clearly, additional studies in rodents and humans using a dose response strategy are necessary to better understand the interplay of steroid hormones including E2, testosterone and progesterone on the regulation of metabolism and insulin action in glucoregulatory tissues. Thus, many questions remain: does E2 enhance skeletal muscle insulin sensitivity and at what minimal pharmacological dose, and what are the critical tissues of E2 action that confer protection against nutrient-induced insulin resistance?
Figure 2: ERα structure (A) and DNA binding at an estrogen response element (ERE) (B) (adapted from [170]).
suggesting transcriptional regulatory mechanisms act over significant physical distances [69,71,72]. Of all the identified sites, 71% harbored putative full estrogen response elements (EREs), 25% ERE half sites, and 4% had no recognizable ERE sequences [69]. Of important consideration, Lin et al. found that only ~20% of the bona fide human ERα binding sites overlapped with whole genome vertebrate alignments suggesting limited conservation of functional ERα binding sites between species [69]. Thus, since most studies interrogating ERα binding on a genome-wide scale are performed in breast cancer cell lines, species, sex, and cell-type specific dynamics of estrogen action should be deliberated.

Classical genetics approaches provide evidence of redundant, additive, and synergistic enhancer relationships over a variety of loci. More recent studies, using a multiplex interference approach (in Ishikawa and T-47D cells), have revealed strong collaboration between predominant and supportive ERα binding sites exposing a complex functional hierarchy of enhancers regulating the expression of ERα target genes [72]. Current thinking is that chromosomal looping allows for the collaborative action of these distal sites and that distance to the target gene and strength of the ERE motif predict the ERα binding site importance [72]. At least in liver, ERE sites, ERE half sites, AP1, bHLH, ETS, and Forkhead-binding motifs were enriched DNA sequences in ERα binding regions [73]. Considering that most of what we know about ERα action is gleaned from MCF7 cells, an important question is whether the genomics of ERα in breast cancer can be translated to muscle and other metabolic tissues [74]. Now that we are moving beyond whole genome binding site cartography, putative ERα binding sites will require validation by functional interrogation using mutagenesis and chromatin immunoprecipitation approaches in a cell specific context [71,72,75–78].

4. THE ROLE OF ERα IN REGULATING INSULIN ACTION AND GLUCOSE DISPOSAL

ESR1 is broadly expressed in the central nervous system and in peripheral tissues including adipose, skeletal muscle, liver, and immune cells [79]. Women and men as well as male and female mice carrying specific ESR1 variants develop features of the metabolic syndrome including obesity, glucose intolerance, and insulin resistance. Clinical evidence is undeniable; the clustering of these metabolic abnormalities increases disease risk (heart disease, type 2 diabetes, and certain forms of cancer) [21,22,80,81]. Of translational relevance, whole body ERα knockout mice (ERαKO) recapitulate the metabolic dysfunction observed in a male human subject with a rare inactivating receptor
mutation, as well as aspects of the phenotypes observed in subjects with genetic polymorphisms in the receptor [21,22,80]. Not only do ERα KO mice have increased adiposity caused by reductions in energy expenditure, but they also exhibit glucose intolerance and insulin resistance, thus demonstrating the critical role for ESR1 in regulating energy and metabolic homeostasis [80–82]. The integration of central and peripheral ESR1 action as well as the interaction of ERα and sex chromosome action remains to be defined; however, the tissue dissection approach to studying ERα using mice with conditional deletion alleles has allowed the research community the opportunity to delineate unique aspects of ERα biology in a tissue and sex-specific context.

Observational findings indicate that ESR1 expression levels are reduced in muscle from women with the metabolic syndrome, and that natural variation in muscle ESR1 expression in women is inversely correlated with adiposity and fasting insulin, markers of metabolic health (i.e. low muscle ESR1 expression levels are associated with metabolic dysfunction and increased adiposity) [83]. Remarkably similar findings were observed across numerous strains of inbred female mice, as well as in genetically obese animals, thereby illustrating the strong relationship between muscle ERα expression and metabolic health. Collectively, these data suggest that maintenance of ERα expression or activation of muscle ESR1 could serve as an effective means to combat diseases associated with metabolic dysfunction [83]. Although these strong correlative findings suggest a relationship between muscle ERα expression levels and metabolic health, few studies have directly tested a causal relationship. Does a loss of ERα specifically from myocytes drive skeletal muscle insulin resistance, or does the insulin resistance phenotype observed in the ERα KO model arise from increased adiposity/alterted adipokine/cytokine secretion and impaired central drive of feeding and ambulatory movement?

Although two forms of the receptor are expressed in many of the glucoregulatory tissues, ERα is expressed at much higher abundance than ERβ or GPR30, as these transcripts are nearly undetectable in muscle from humans and rodents [46,83–85]. Consistent with these observations, homozygous deletion of ERα failed to produce insulin resistance [86] in contrast to the marked skeletal muscle insulin resistance observed in ERα KO animals (Figure 4) [81,87]. The underlying mechanism contributing to impaired insulin action in muscle of ERα KO animals remains disputed. Findings reported by Bryzgalova et al. [82] suggest reduced total GLUT4 levels in muscle as an underlying cause for the ERα KO insulin resistance phenotype; however, these findings were not supported by Ribas et al. [81]. Furthermore, despite maintenance of GLUT4 mRNA and protein, Ribas et al. reported more dramatic skeletal muscle insulin resistance in ERα KO mice than Bryzgalova et al. Hevener and colleagues suggest that the skeletal muscle insulin resistance observed in ERα KO mice is predominantly a consequence of direct ERα deletion effects on insulin action with a secondary impact of inflammation on proximal insulin signaling. This hypothesis was later confirmed using muscle-conditional deletion alleles studied in vivo, ex vivo, and in vitro.

Indeed, in female muscle-specific ERα knockout mice and myotubes with ERα knockdown, no alteration in GLUT4 mRNA or protein in skeletal muscle was observed despite reduced insulin-stimulated glucose disposal into muscle during clamp studies. Findings in the muscle-specific ERα mouse are consistent with those of whole body ERα mice [88]. Furthermore, additional studies by Barros et al. [57,89] assessing GLUT4 expression in response to ovariectomy with/without E2 supplementation are in conflict with other studies of similar design.
Given the lack of consensus ERE in the GLUT4 promoter \[93\] and absence of confirmatory findings in cellular reporter and chromatin immunoprecipitation assays, the regulation of GLUT4 expression by ER\(\alpha\) requires further investigation. GLUT4 is regulated by several redundant transcriptional pathways \[94,95\]. Considering that total GLUT 4 transcript and protein levels are not reduced in humans or rodents in the context of insulin resistance, obesity, and type 2 diabetes, or between men and women \[96,97\], it is likely that in the absence of ER\(\alpha\), other transcription factors compensate to maintain GLUT4 levels \[98—103\]. This is not to say that ER\(\alpha\) is not involved in the exercise-stimulated increase in GLUT4 observed following training \[96,104,105\], given the concomitant increase in ER\(\alpha\) expression observed in muscle of exercise-trained humans and mice \[84,106,107\].

Myocyte enhancer factor 2 (MEF2) expression and a functional MEF2 element in the GLUT4 promoter are critical for GLUT4 gene expression \[108\]. Furthermore, reciprocal regulation between ER\(\alpha\) and MEF2 is observed in cardiomocytes via ER\(\alpha\) interaction with class II HDAC in female mice only \[109\]. Despite complex transcriptional signal integration in the regulation of GLUT4 expression \[94,95,110—113\], it is conceivable that elevated ER\(\alpha\) action could promote increased GLUT4 transcription via heightened protein tethering with MEF2 on the GLUT4 promoter or by indirect action via AMPK \[43,114\]. It is important to note that transcriptional activity of the GLUT4 promoter is quite low under basal conditions, and other ovarian hormones (e.g. progesterone) are shown to play an antagonistic role in the regulation of GLUT4 expression \[39\]. These issues as well as the dose of E\(\text{2}\) administration during interventional studies (presumably off-target effects of superphysiological doses of E\(\text{2}\) are deleterious to metabolism), the age and hormone status of the human subjects and rodents (species and strain) used are important considerations when interpreting the literature.

Considering the varying roles that muscle and adipose tissue play in controlling whole body metabolic homeostasis, it is likely that the interplay of transcriptional regulators of GLUT4 vary markedly between tissues. Taken together, these data would suggest a potential role for ER\(\alpha\) as an enhancer of GLUT4 transcription in muscle under certain conditions, but not necessarily obligatory in the direct regulation of GLUT4 expression under basal conditions.

Collectively, work by Ribas et al. suggests that the skeletal muscle insulin resistance observed in whole body ER\(\alpha\)KO mice and animals with a muscle-specific deletion of ER\(\alpha\) is predominantly the result of impaired insulin signal transduction (Figure 5) \[88\]. A role for ER\(\alpha\) in the regulation of proximal insulin signal transduction has been suggested previously as E\(\text{2}\) administration to insulin resistant rodents increases insulin receptor substrate (IRS)-1 abundance and insulin-stimulated tyrosine phosphorylation and as well as phosphorylation of Akt at activation site Ser473 \[87,115\]. Akt serves many functions in myocytes including ER\(\alpha\)-induced regulation of myogenic differentiation \[116\], suppression of muscle-atrophy ubiquitin ligases via FOXO1 inhibition \[117\], and induction of genes associated with myocellular

**Figure 5:** The impact of skeletal muscle-specific ER\(\alpha\) deletion on metabolism and insulin sensitivity. Skeletal muscle-specific ER\(\alpha\) deletion reduced mitochondrial DNA replication and impaired muscle oxidative metabolism, despite maintenance of mtDNA copy number. Increased PKA and reduced calcineurin activity promoted elongated, hyperfused mitochondria in MERKO muscle. The morphological changes coupled with an imbalanced PKA-calcineurin axis blunted mitochondrial fission signaling through DRP1 and impaired macroautophagy, both processes critical for mitochondrial turnover by mitophagy. Collectively, the retention of damaged mitochondria to the network was paralleled by increased ROS production, inflammation, and insulin resistance in skeletal muscle of MERKO mice. Findings implicate a critical role for ER\(\alpha\) in the maintenance of muscle mitochondrial and metabolic health \[83\].
proliferation [116,118–121]. In breast cancer cell lines, endothelial cells, and cortical neurons, ERα-specific binding and activation of PI3K kinase as well as suppression of the tumor suppressor and PI3K/nase inhibitory protein, PTEN, is well-established [122–126]; however, studies on this direct interaction are limited in skeletal muscle. Additionally, E2 acting via ERα is also shown to promote phosphorylation of p38 MAPK [127,128], and transduction of a signaling cascade shown to enhance GLUT4 intrinsic activity and glucose uptake [129–131]. Furthermore, ERα activation of Akt and MAPK pathways is thought to underlie E2-mediated protection of muscle against age-induced sarcopenia [132–138], exercise-induced muscle damage [120,134,139,140], and myocyte apoptosis in the face of a variety of cellular perturbations [141–144]. Thus, ERα stimulation of muscle growth and insulin sensitivity via these pathways is reasonable to posit.

5. ERα AND SKELETAL MUSCLE FATTY ACID METABOLISM AND INFLAMMATION

Normally cycling pre-menopausal women are protected against acute lipid-induced insulin resistance compared with estrogen-deficient women and men [38,145]. Furthermore, muscle from premeno- pausal women shows enhanced insulin sensitivity despite 47% higher triglyceride content compared with age-matched men [97]. This observation in women, is consistent with a reduced respiratory quotient and greater reliance on fatty acids as a fuel source [146]. These data indicate interesting similarities between E2 replete women and exercise trained subjects including elevated muscle ERα expression [84,106,107], heightened insulin sensitivity [101], elevated muscle lipid tolerance [147], and enhanced oxidative capacity [148,149]. Consistent with the reported effects of E2 on metabolism, estrogen supplementation is shown to enhance lipid oxidation in vivo in men during acute endurance exercise [150], and palmitate oxidation in myotubes from male subjects ex vivo [46]. The effect of E2 to increase the expression of fatty acid transport protein FAT/CD36 and FABP as well as transcription factors and key enzymes that regulate oxidative metabolism [90,96,151] likely underlie these observations in male subjects. Moreover, E2 treatment reduced HFD-induced insulin resistance in skeletal muscle by 50% (assessed by hyperinsulinemic-euglycemic clamp) in an ERα-dependent manner [87]. In addition, similar to exercise, E2 is shown to rapidly stimulate AMPK phosphorylation in both muscle and myotubes in culture [43,152]. AMPK is considered a central regulator of many cellular processes including growth, mitochondrial biogenesis, and oxidative metabolism [153,154]. Comparable to the effects of E2, the ERα-selective agonist PPT stimulates AMPK phosphorylation in muscle of ovariectomized female rats [42] while O VX or whole body ERα deletion is associated with reduced skeletal muscle levels of phosphorylated AMPK [81,155]. Recent evidence from Lipovka et al. shows that ERα but not β directly binds the β-y-subunit domain of AMPK α [156]. Muscle PPARγ, PPARδ, and UCP2 expression are also reduced in whole body ERαKO mice suggesting that E2 acting via ERα is essential in the regulation of a coordinated program regulating oxidative metabolism. Interestingly, although the phenotype of impaired muscle fatty oxidation was recapitulated in the muscle-specific ERαKO mice (MERKO), no alteration in basal p-AMPK, PPARα, PPARδ, or UCP2 was observed [88], suggesting that these specific alterations in gene expression are secondary to the loss of ERα in other metabolic tissues (e.g. CNS, adipose tissue, or liver). The mechanistic link between the accumulation of lipid intermediates, activation of inflammatory signaling cascades, and impaired insulin action is shown in myocytes and rodent muscle, and these factors are observed concurrently in obese, type 2 diabetic subjects [157–160] as well as in muscle from whole body and muscle-specific ERαKO mice [81]. Bioactive lipid intermediates including diacylglycerol, DAG, and ceramides are believed to activate stress kinases including IKKβ, c-Jun-N-terminal kinase (JNK), and certain nPKCs [158,161–163]. Indeed, muscle from normal chow-fed whole body ERαKO mice showed heightened inflammatory signaling as reflected by markedly increased JNK phosphorylation and TNFα transcript [81]. A similar inflammatory profile was observed in muscle from female MERKO mice [83]. Collectively, these data illustrate the essential role of ERα is regulating fatty acid oxidation (FAO) and inflammation in muscle and highlight the primary nature of ERα in the direct control of these processes. The impact of pathway crossstalk and other cellular signaling mechanisms engaged in altering FAO and inflammation in the context of ERα deficiency, are not well fleshed out. In addition to the action of ERα on enzymes involved in fatty acid transport and processing, new evidence is emerging regarding the direct role of ERα on oxidative metabolism via control over specific mitochondrial processes (discussed in greater detail below) [83]. With respect to inflammatory signaling activation, beyond ERα de-repression of selective inflammatory targets within the nucleus, it is likely that mitochondrial ROS production, sarcoplasmic reticulum stress, and proinflammatory lipid species are additional mediators of heightened inflammation in muscle.

6. THE ROLE OF MUSCLE ERα IN THE REGULATION OF MITOCHONDRIAL FUNCTION

Despite model differences in gene and protein expression, skeletal muscle insulin resistance and bioactive lipid accumulation was surprisingly similar between ERαKO and MERKO animals [81,83]. Triacylglycerol, diacylglycerol, and ceramides were all elevated significantly in muscle from female mice lacking ERα globally or specifically in muscle [81,83]. Consistent with these observations, oxygen consumption rates in C2C12 myotubes with ERα knockdown (KD) were reduced significantly [83]. In addition, mitochondria from muscle cells depleted of ERα produced high levels of reactive oxygen species (ROS) thus promoting cellular oxidative stress. Analysis of mitochondrial function confirmed a defect in respiratory complex 1 activity in MERKO muscle [83]. Moreover, mitochondria from MERKO mice produced increased levels of H2O2 and superoxide, thus recapitulating findings in C2C12 myotubes with Esr1-KD. This defect in mitochondrial function was paralleled by a reduction in expression of the only mammalian mitochondrial (mt) DNA polymerase, Polg1, in both MERKO muscle as well as murine myotubes with Esr1 knockdown (Figure 5). Additionally, heavy water labeling of newly synthesized mtDNA showed a reduction in the rate of mtDNA replication, functionally supporting an impact of the reduction in Polg1 expression in MERKO mouse muscle [83]. Additional mechanistic studies showed that estradiol and ERα-selective ligand treatment induced Polg1 expression in muscle cells; however, the ligand was ineffective to induce gene expression when the receptor was absent. Considering the presence of a consensus ERE in the Polg1 promoter, ongoing studies in the Hevener laboratory will delineate the mecha- nism(s) by which ERα regulates mtDNA replication via this polyomerase. mtDNA replication is intimately linked with mitochondrial remodeling by a process known as fission [164]. The Hevener laboratory has shown that treatment of murine myotubes with ERα agonists also promotes this mitochondrial morphological alteration inducing the severing of a mitochondrion into two daughter organelles achieved
by high order dynamin related protein (Drp) 1 oligomers promoting scission. Interestingly, although ERα activation drives mitochondrial fission, it appears to achieve this shift in mitochondrial architecture by a coordinated enzymatic regulation of the fission activator calcineurin and the calcineurin inhibitor Rcan1 [83]. Supporting the role of ERα in the regulation of mitochondrial morphology, we observed that mitochondria from both female and male MERKO mouse muscle were enlarged, elongated, and hyperfused, suggesting a reduction in fission:fusion dynamics. Internally consistent with the morphological data obtained by transmission electron microscopy, analysis of mitochondrial dynamics signaling showed reduced fission signaling by Drp1 (including increased phosphorylation at the inhibitory Ser637 site and reduced total Drp1 protein on the outer mitochondrial membrane), as well as increased abundance of the inner and outer mitochondrial membrane fusion proteins OPA1 and Mfn2 [83] (Figure 5). Ribas et al. observed a marked increase in expression of the mitochondrial fission inhibitor Rcan1 in myotubes with Esr1-KD, female MERKO muscle, and muscle from women displaying clinical features of the metabolic syndrome. Ribas et al. overexpressed Rcan1 in myotubes using lentivirus and showed that Rcan1 expression elevated to levels seen in MERKO mouse muscle impaired insulin action [83]. Moreover, impairment in muscle mitochondrial fission promoted dysfunction in mitochondrial respiration and insulin action in primary myotubes from female mice with Dnm1L deletion and in C2C12 myotubes with lentiviral-mediated Dnm1L knockdown [83]. Therefore, we hypothesize that both a reduction in the direct effects of ERα on insulin signaling as well as indirect effects of ERα on insulin action mediated by mitochondrial dysfunction contribute to the development of global disturbances in metabolic health and insulin sensitivity (Figure 5).

In light of the observation that Rcan1 was only induced in female MERKO muscle (not in males) despite a similar impairment in fission signaling in both sexes of MERKO mice, the Hevener laboratory has initiated additional studies to flesh out the sex-specific mechanisms that underlie altered mitochondrial dynamics and function in the absence of ERα. These studies are viewed to be of translational importance since it is well known that sex is an important biological variable contributing to differences in disease incidence and mechanisms of pathobiology. Follow-up studies in the Hevener laboratory in MERKO mice, as well as new studies in muscle-specific Polg1, Parkin (Park2), and Drp1 (Dnm1L) KOs, and mice with muscle-specific ERα overexpression, will allow for the determination of whether the stall in mtDNA replication is a primary defect driving mitochondrial dysfunction and insulin resistance. Secondly, we will learn whether the impairment in mitochondrial quality control and turnover seen in MERKO muscle is a consequence or causal of the stall in mtDNA replication, and contributory or resultant of insulin resistance. The use of broad transcriptomic, proteomic and metabolomic approaches in rodents harboring conditional ERα deletion alleles coupled with more targeted chromatin immunoprecipitation analyses in ERα ligand treated animals will allow for the identification of novel ERα target genes as well as reveal new mechanism(s) controlling metabolic signaling nodes in insulin responsive tissues.

7. THE ROLE OF ERα IN THE REGULATION OF MUSCLE PERFORMANCE AND EXERCISE TRAINING

In addition to the skeletal muscle-induced insulin resistance, MERKO mice also fail to adapt to endurance training (Figure 6). Whether defects in exercise training are linked with impaired mitochondrial function and disruption of calcium homeostasis is unclear. In addition to diminished muscular endurance in MERKO, Lai and Collins showed that ERα deficient muscles are also fast fatiguing and have reduced performance capability [165,166] (Figure 6). Studies from this group...
show that E\textsubscript{2}, in a concentration-dependent manner, elevates phosphorylation of the myosin regulatory light chain (pRLC) in C2C12 myotubes in culture and in muscles from C57BL/6J mice [166]. Female mice with a skeletal muscle-specific KO of ER\textalpha produced 16% less eccentric and 16–26% less submaximal and maximal isometric force with impaired force recovery relative to WT mice. Maximal torque production by planter- and dorsi-flexors were 16% and 12% lower in female KO than WT mice, and produced 21–32% less power, and submaximal isometric and peak concentric torques [166]. Data support the hypothesis that ablation of ER\textalpha in skeletal muscle underlies muscle weakness, suggesting that the beneficial effects of estradiol on muscle strength are receptor mediated via ER\textalpha. Since metabolic function is clearly linked with muscle quality and mass, and these traits are most highly associated with morbidity and mortality in aging, strategies aimed at maintaining muscle metabolism appear warranted especially in women during the menopausal transition.

8. CONCLUSIONS AND PERSPECTIVES

In recent years, novel molecular targets have emerged offering the prospect of pharmacological intervention to restore metabolic homeostasis and insulin action, as well as ameliorate complications associated with type 2 diabetes and obesity. The inherent beauty of targeting ER\textalpha therapeutically is underscored by decades of research and in depth knowledge related to biological/clinical efficacy and toxicity profiles obtained for estradiol/SERMs during preclinical studies in animal models and clinical trials in human subjects. Although estrogen treatment (primarily 17\beta-estradiol) is shown to promote energy homeostasis, improve body fat distribution, and diminish insulin resistance, \beta-cell dysfunction and inflammation, the challenge with chronic hormone administration is the narrow therapeutic index. Thus, the translation of the basic advances in diabetes and obesity treatment described in this review, although successful in rodents, is problematic when extending to clinical practice. However, ten years after the WHI concluded that the risks of hormone therapy outweighed its benefits, reevaluation of the WHI findings and determination that the risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism with estrogen-progestin treatment were overstated, prompted a position statement by the North American Menopause Society stating that HRT has a role in short-term treatment of menopausal symptoms [167]. Thus, considering the new and more positive light estradiol is receiving by clinical experts, it will be important to determine whether short-term treatment with a well-designed ER\textalpha agonist during early menopause offers protection against metabolic dysfunction and insulin resistance.

Additionally, it is imperative that we determine how to modulate the specific ER-controlled pathways involved in energy balance and glucose homeostasis and develop estradiol mimetics that initiate specific cellular events promoting metabolic benefit without unwanted side effects. This could possibly be achieved by fusion peptides [168,169] or through the development of novel SERMs that retain the beneficial metabolic effects of E\textsubscript{2} in desired tissues including skeletal muscle, while exerting antagonist action in breast and uterus. With regard to whole body metabolism, obesity, and insulin sensitivity, future studies should focus on identifying the critical nodes of ER\textalpha-mediated metabolic crosstalk between all glucoregulatory tissues as these integrative networks may reveal new pharmacological targets for therapeutic exploitation.

Although this review focused on the role of ER\textalpha in controlling metabolism and insulin action in skeletal muscle, clearly the expression of ER\textalpha in other metabolic tissues contributes to specific aspects of global metabolism and metabolic health. Once the general phenotype of each of the ER\textalpha deletion models is published, it will be important to integrate the findings so that the field has a better perspective on the tissue selective contribution of ER\textalpha to a phenotypic trait. Determination of the overlapping and distinctive phenotypic traits of conditional ER\textalpha deletion models will allow the field to better target ER\textalpha for global impact. Since insulin resistance underlies most chronic diseases, the Hever laboratory has focused its efforts on understanding pathways known to impair insulin action including inflammation, and organelle, metabolic, and oxidative stress. Although collective evidence suggests that ER\textalpha regulates a vast number of metabolic processes, emerging findings suggest that ER\textalpha exerts a primary regulatory role on metabolism by controlling specific aspects of mitochondrial function. Now that novel technologies allow us to study this complex organelle in a more precise and comprehensive way, a new era of mitochondrial biology has emerged. A major area of focus for diabetes researchers is to understand the genes that regulate key aspects of mitochondrial function and determine how this organelle controls other pathways including insulin action, inflammation, adiposity and muscle mass.

Lastly, a major limitation in our understanding and interpretation of E\textsubscript{2}–ER\textalpha action is the lack of information regarding the contribution of extranuclear vs. nuclear ER\textalpha actions, as well as ligand vs. non-ligand-mediated functions of ERs in controlling key metabolic nodes in insulin responsive tissues. Delineation of these pathways will be critical for moving the field forward and advancing therapeutic strategies to improve women’s health.

ACKNOWLEDGEMENTS

This work was supported by grants from the National Institutes of Health (DK89109 and DK063491), the NIH Nuclear Receptor Signaling Atlas (U24DK097743 NURSA NIDSP), UCLA Department of Medicine, UCLA Iris–Cantor Women’s Health Foundation, and the UCLA Jonsson Comprehensive Cancer Center. We would like to acknowledge all of the terrific research performed by many of our esteemed colleagues in the fields of nuclear receptor biology and integrative metabolism; however, due to page limits, we were unable to cite a large number of studies. We would like to take this opportunity to thank Dr. Kenneth Korach for his generous support of our research and for providing us with the ER\textalpha floxed mouse as well as a variety of powerful molecular tools. We would also like to thank Drs. Ronald Evans, Christopher Glass, and Jerrold Olefsky for helpful discussions and intellectual contributions to our research over the years.

CONFLICT OF INTEREST

None declared.

REFERENCES

[1] Bonds, D.E., Lasser, N., Qi, L., Brzyski, R., Caan, B., Heiss, G., et al., 2006. The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial. Diabetologia 49:459–468.
[2] Kanaya, A.M., Herrington, D., Vittinghoff, E., Liu, F., Grady, D., Bittner, V., et al., 2003. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 138:1–9.
[3] Margolis, K.L., Bonds, D.E., Rodabough, R.J., Tinker, L., Phillips, L.S., Allen, C., et al., 2004. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:1175–1187.
[4] Szmuiłowicz, E.D., Stuenkel, C.A., Seely, E.W., 2009. Influence of menopause on diabetes and diabetes risk. Nature Reviews Endocrinology 5:553–558.
Review

[5] Penti, K., Tuppurainen, M.T., Honkanen, R., Sandini, L., Kroger, H., Alhava, E., et al., 2009. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. European Journal of Endocrinology 160:979–983.

[6] Mauvais-Jarvis, F., Manson, J.E., Stevenson, J.C., Fonseca, V.A., 2017. Menopausal hormone therapy and type 2 diabetes prevention: evidence, mechanisms, and clinical implications. Endocrine Reviews 38:173–188.

[7] Salpeter, S.R., Walsh, J.M., Orniston, T.M., Greyber, E., Buckley, N.S., Salpeter, E.E., 2006. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obesity Metabolism 8:538–554.

[8] Thornton, J.W., 2001. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proceedings of the National Academy of Sciences of the U S A 98: 5671–5676.

[9] O’Malley, B.W., 1971. Mechanisms of action of steroid hormones. New England Journal of Medicine 284:370–377.

[10] Nilsson, S., Makela, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., et al., 2001. Mechanisms of estrogen action. Physiological Reviews 81: 1535–1565.

[11] Safe, S., Kim, K., 2008. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. Journal of Molecular Endocrinology 41:263–275.

[12] Seiler-Tuyns, A., Walker, P., Martinez, E., Merillat, A.M., Givel, F., Wahli, W., 2003. Identification of estrogen-responsive DNA sequences by transient expression experiments in a human breast cancer cell line. Nucleic Acids Research 14:8755–8770.

[13] Charn, T.H., Liu, E.T., Chang, E.C., Lee, Y.K., Katzenellenbogen, J.A., Katzenellenbogen, B.S., 2010. Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Molecular Endocrinology 24:47–59.

[14] Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., Brown, M., 2000. Cofactor dynamics and efficiency in estrogen receptor-regulated transcription. Cell 103: 843–852.

[15] Hammes, S.R., Levin, E.R., 2007. Extraneous nuclear steroid receptors: nature and actions. Endocrine Reviews 28:726–741.

[16] Levin, E.R., 2015. Extraneous steroid receptors are essential for steroid hormone actions. Annual Review of Medicine 66:271–280.

[17] Tiano, J.P., Mauvais-Jarvis, F., 2012. Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nature reviews Endocrinology.

[18] Ronda, A.C., Boland, R.L., 2016. Intracellular distribution and involvement of GPR30 in the actions of E2 on C2C12 cells. Journal of Cellular Biochemistry 117:793–805.

[19] Liu, S., Mauvais-Jarvis, F., 2010. Minireview: estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 151:859–864.

[20] Pedram, A., Razandi, M., Blumberg, B., Levin, E.R., 2016. Membrane and nuclear estrogen receptor alpha collaborate to suppress adipogenesis but not triglyceride content. The FASEB Journal 30:230–240.

[21] Smith, E.P., Boyd, J., Frank, G.R., Takahashi, H., Cohen, R.M., Specker, B., et al., 1994. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New England Journal of Medicine 331:1056–1061.

[22] Okura, T., Koda, M., Ando, F., Niino, N., Shimokata, H., 2003. Association of the mitochondrial DNA 15497G/A polymorphism with obesity in a middle-aged and elderly Japanese population. Human Genetics 113: 432–436.

[23] Yamada, Y., Ando, F., Niino, O., Ohta, S., Shimokata, H., 2002. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density of the femoral neck in elderly Japanese women. Journal of Molecular Medicine 80:452–460.

[24] DeFronzo, R.A., Bonadonna, R.C., Ferramini, E., 1992. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15:318–368.

[25] Miranda, P.J., DeFronzo, R.A., Califf, R.M., Guyton, J.R., 2005. Metabolic syndrome: definition, pathophysiology, and mechanisms. American Heart Journal 149:33–45.

[26] Alhava, E., et al., 2009. Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study. European Journal of Endocrinology 160:979–983.

[27] Casazza, K., Page, G.P., Fernandez, J.R., 2010. The association between the rs2234693 and rs9340799 estrogen receptor alpha gene polymorphisms and risk factors for cardiovascular disease: a review. Biological Research for Nursing 12:84–97.

[28] Okura, T., Koda, M., Ando, F., Niino, N., Tanaka, M., Shimokata, H., 2003. Association of the mitochondrial DNA 15497G/A polymorphism with obesity in a middle-aged and elderly Japanese population. Human Genetics 113: 432–436.

[29] Campbell, S.E., Febbraio, M.A., 2002. Effect of the ovarian hormones on GLUT4 expression and contraction-stimulated glucose uptake. American Journal of Physiology Endocrinology and Metabolism 282: E1139–E1146.
[40] Stubbs, R.E., Holcomb, V.B., Hong, J., Nunez, N.P., 2011. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. European Journal of Nutrition, 50:241–254.

[41] Hamilton, D.J., Minza, L.J., Kumar, T., Cao, T.N., Lyon, C.J., Geiger, P.C., et al., 2016. Estrogen receptor alpha activation enhances mitochondrial function and systemic metabolism in high-fat-fed ovarxciated mice. Physic Reports 4.

[42] Gorres, B.K., Bohnhoff, G.L., Morris, J.K., Geiger, P.C., 2011. In vivo stimulation of oestrogen receptor alpha increases insulin-stimulated skeletal muscle glucose uptake. Journal of Physiology 589:2041–2054.

[43] Rogers, N.H., Witzczak, C.A., Hirshman, M.F., Goodyear, L.J., Greenberg, A.S., 2009. Estradiol stimulates Akt, AMP-activated protein kinase (AMPK) and TBC1D1/4, but not glucose uptake in rat soleus. Biochemical and Biophysical Research Communications 382:646–650.

[44] Van Pelt, R.E., Goyasky, W.S., Schwartz, R.S., Koth, W.M., 2003. Intravenous estrogen increases insulin clearance and action in postmenopausal women. American Journal of Physiology Endocrinology and Metabolism 285: E311–E317.

[45] Alonso, A., Gonzalez-Pardo, H., Garrido, P., Conejo, N.M., Llaneza, P., Diaz, F., et al., 2010. Acute effects of 17 beta-estradiol and genistein on insulin sensitivity and spatial memory in aged ovarxciated female rats. Age (Dordr) 32:421–434.

[46] Salehzadeh, F., Rune, A., Osler, M., Al-Khalili, L., 2011. Testosterone or 17 beta-estradiol exposure reveals sex-specific effects on glucose and lipid metabolism in human myotubes. Journal of Endocrinology 210:219–229.

[47] Park, Y.M., Pereira, R.I., Erickson, C.B., Swibas, T.A., Kang, C., Van Pelt, R.E., 2017. July Time sex hormone and skeletal muscle estrogen receptors, PGC-1alpha, and AMPK. Menopause 24(7):815–823. [https://doi.org/10.1097/GME.0000000000000820]

[48] Rochira, V., Madeso, B., Zirilli, F., Caffagni, G., Maffei, L., Carani, C., 2007. Oestriadiol replacement treatment and glucose homeostasis in two men with congenital aromatase deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin sensitivity in men. Diabetic Medicine 24:1491–1495.

[49] Jones, M.E., Thorburn, A.W., Britt, K.L., Hewitt, K.N., Wreford, N.G., Proietto, J., et al., 2000. Aromatase deficiency in men: Reinforced evidence on the relationship between congenital aromatase deficiency, adiposity and the metabolic syndrome. Clin Endocrinol 59:1273–12740.

[50] Guercio, G., Di Palma, M.I., Pepe, C., Saraco, N.J., Prieto, M., et al., 2009. Metformin, estrogen replacement therapy and gonadotropin inhibition fail to improve insulin sensitivity in a girl with aromatase deficiency. Hormone Research 72:370–376.

[51] Takeda, K., Toda, K., Saibara, T., Nakagawa, M., Saika, K., Onishi, T., et al., 2003. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. Journal of Endocrinology 176: 237–246.

[52] Maffei, L., Murata, Y., Rochira, V., Tubert, G., Aranda, C., Vazquez, M., et al., 2004. Dysmethylated syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. Journal of Clinical Endocrinology & Metabolism 89:61–70.

[53] Maffei, L., Rochira, V., Zirilli, L., Antunez, P., Aranda, C., Fabre, B., et al., 2007. A novel compound heterozygous mutation of the aromatase gene in an adult man: reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome. Clin Endocrinol (Oxford) 67:218–224.

[54] Jones, M.E., McInnes, K.J., Boon, W.C., Simpson, E.R., 2007. Estrogen and adiposity—utilizing models of aromatase deficiency to explore the relationship. The Journal of Steroid Biochemistry and Molecular Biology 106:3–7.

[55] Morishima, A., Grumbach, M.M., Simpson, E.R., Fisher, C., Qin, K., 1995. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Journal of Clinical Endocrinology & Metabolism 80:3689–3698.

[56] Nadal, A., Alonso-Magdalena, P., Soriano, S., Quesada, I., Ropero, A.B., 2009. The pancreatic beta-cell as a target of estrogens and xenoestrogens: implications for blood glucose homeostasis and diabetes. Molecular and Cellular Endocrinology 304:63–68.

[57] Barros, R.P., Morani, A., Marisot, A., Machado, U.F., 2008. Insulin resistance of pregnancy involves estrogen-induced repression of muscle GLUT4. Molecular and Cellular Endocrinology 295:24–31.

[58] Ding, E.L., Song, Y., Mansor, J.E., Rifai, N., Buring, J.E., Liu, S., 2007. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetesologia 50:2076–2084.

[59] Kalyani, R.R., Frano, M., Dobs, A.S., Ouyang, P., Vaidya, D., Bertoni, A., et al., 2009. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. Journal of Clinical Endocrinology & Metabolism 94:4127–4135.

[60] Jensen, E.V., Jacobson, H.I., Wal, A.A., Frye, C.A., 2010. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiology & Behavior 99:151–162.

[61] Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., Gustafsson, J.A., 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the U S A 93:5925–5930.

[62] Jia, M., Dahlman-Wright, K., Gustafsson, J.A., 2015. Estrogen receptor alpha and beta in health and disease. Best Practice & research Clinical Endocrinology & Metabolism 29:557–568.

[63] Arnal, J.F., Fontaine, C., Aboit, A., Valera, M.C., Laurell, H., Goudry, P., et al., 2013. Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo. Steroids 78:576–582.

[64] Liao, S., 1975. Cellular receptors and mechanisms of action of steroid hor- mones. International Review of Cytology 41:87–172.

[65] Chen, J.Q., Delannoy, M., Cooke, C., Yager, J.D., 2004. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. American Journal of Physiology Endocrinology and Metabolism 286:E1011–E1022.

[66] Green, S., Walter, P., Greene, G., Krust, A., Goffin, C., Jensen, E., et al., 1986. Cloning of the human oestrogen receptor cDNA. Journal of Steroid Biochemistry 27:77–83.

[67] Carroll, J.S., Brown, M., 2006. Estrogen receptor target gene: an evolving concept. Molecular Endocrinology 20:1707–1714.

[68] Carroll, J.S., Meyer, C.A., Song, J., Li, W., Geistlinger, T.R., Eccleshoute, J., et al., 2006. Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38:1289–1297.

[69] Lin, C.Y., Vega, V.B., Thomsen, J.S., Zhang, T., Kong, S.L., Xie, M., et al., 2007. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genetics 3:e67.

[70] Bourdeau, V., Deschenes, J., Metivier, R., Nagai, Y., Nguyen, D., Bretschneider, N., et al., 2004. Genome-wide identification of high-affinity estrogen response elements in human and mouse. Molecular Endocrinology 18:1411–1427.

[71] Fullwood, M.J., Liu, M.H., Pan, Y.F., Liu, J., Xu, H., Mohamed, Y.B., et al., 2009. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462:58–64.

[72] Carleton, J.B., Berrett, K.C., Gertz, J., 2017. Multiplex enhancer interference reveals collaborative control of gene regulation by estrogen receptor alpha-bound enhancers. Cell Syst 5:330–344 e335.

[73] Gao, H., Falt, S., Sandelin, A., Gustafsson, J.A., Dahlman-Wright, K., 2008. Genome-wide identification of estrogen receptor alpha-binding sites in mouse liver. Molecular Endocrinology 22:10–22.

[74] Droog, M., Mersink, M., Zwart, W., 2016. The estrogen receptor alpha cistrome beyond breast cancer. Molecular Endocrinology 30:1046–1058.
[75] Welboren, W.J., Sweep, F.C., Span, P.N., Stunnenberg, H.G., 2009. Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocrine Related Cancer 16:1073–1089.

[76] Welboren, W.J., van Driel, M.A., Janssen-Megens, E.M., van Heeringen, S.J., et al., 2009. CHIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. The EMBO Journal 28:1418–1428.

[77] Andersson, R., Gehbard, C., Miguel-Escalada, I., Hoef, I., Bornholdt, J., Boyd, M., et al., 2014. An atlas of active enhancements across human cell types and tissues. Nature 507:455–461.

[78] Liu, Z., Merkurjev, D., Yang, F., Li, W., Oh, S., Friedman, M.J., et al., 2014. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 159:356–373.

[79] Kuiper, G.G., Carlsson, B., Grandien, K., Enmark, E., Hagglund, J., Nilsson, S., et al., 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863–870.

[80] Heine, P.A., Taylor, J.A., Iwamoto, G.A., Lubahn, D.B., Cooke, P.S., 2000. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proceedings of the National Academy of Sciences of the United States of America 97:12729–12734.

[81] Ribas, V., Nguyen, M.T., Henstridge, D.C., Nguyen, A.K., Beaven, S.W., Wiik, A., Gustafsson, T., Esbjornsson, M., Johansson, O., Ekman, M., Riant, E., Waget, A., Cogo, H., Arnal, J.F., Burcelin, R., Gourdy, P., 2009. Estrogen and metabolic resistance in rats. The Journal of Steroid Biochemistry and Molecular Biology 112:1273–1278.

[82] Bryzgalova, G., Gao, H., Ahren, B., Zierath, J.R., Galuska, D., Steiler, T.L., et al., 2006. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia 49:588–597.

[83] Ribas, V., Drew, B.G., Zhou, Z., Phun, J., Kalajian, N.Y., Soleymani, T., et al., 2016. Skeletal muscle action of estrogen receptor alpha is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. Science Translational Medicine 8:1–21.

[84] Wik, A., Gustafsson, T., Esbjornsson, M., Johansson, 0., Ekman, M., Sundberg, C.J., et al., 2005. Expression of oestrogen receptor alpha and beta is higher in skeletal muscle of highly endurance-trained than of moderately active men. Acta Physiologica Scandinavica 184:105–112.

[85] Baltgalvis, K.A., Greising, S.M., Warren, G.L., Lowe, D.A., 2010. Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. PLoS One 5:e10164.

[86] Ohlsson, C., Hellberg, N., Parini, P., Vidal, O., Bohlooly, Y.M., Rudling, M., et al., 2000. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochemical and Biophysical Research Communications 278:640–645.

[87] Riant, E., Waget, A., Cogo, H., Arnal, J.F., Burcelin, R., Gourdy, P., 2009. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 150:2109–2117.

[88] Ribas, V., Drew, B.G., Soleymani, T., Darai, P., Hevener, A., 2010. Skeletal muscle specific ER alpha deletion is causal for the metabolic syndrome. Endocrine Reviews 31:55.

[89] Barros, R.P.A., Machado, U.F., Warner, M., Gustafsson, J.-Å., 2006. Muscle GLUT4 regulation by estrogen receptors ERβ and ERα. Proceedings of the National Academy of Sciences of the United States of America 103:1605–1608.

[90] Campbell, S.E., Mehan, K.A., Tunstall, R.J., Febbraio, M.A., Cameron-Smith, D., 2003. 17β-estradiol upregulates the expression of peroxisome proliferator-activated receptor alpha and lipid oxidative genes in skeletal muscle. Journal of Molecular Endocrinology 31:37–45.

[91] Alonso, A., Ordonez, P., Fernandez, R., Moreno, M., Llaneza, P., Patterson, A.M., et al., 2009. 17β-estradiol treatment is unable to reproduce p5α redistribution associated with gestational insulin resistance in rats. The Journal of Steroid Biochemistry and Molecular Biology 116:160–170.

[92] Hansen, P.A., McCarthy, T.J., Pasia, E.N., Spina, R.J., Gulve, E.A., 1996. Effects of ovariectomy and exercise training on muscle GLUT-4 content and glucose metabolism in rats. Journal of Applied Physiology 80:1605–1611.

[93] Barros, R.F., Gustafsson, J.A., 2011. Estrogen receptors and the metabolic network. Cell Metabolism 14:289–299.

[94] Murgia, M., Jensen, T.E., Cuzinato, M., Garcia, M., Richter, E.A., Schiaffino, S., 2009. Multiple signalling pathways redundantly control glucose transporter GLUT4 gene transcription in skeletal muscle. The Journal of Physiology 587:4319–4327.

[95] Zorzano, A., Palacin, M., Guma, A., 2005. Mechanisms regulating GLUT4 glucose transporter expression and glucose transport in skeletal muscle. Acta Physiologica Scandinavica 183:43–58.

[96] Fu, M.H., Maher, A.C., Hamadheh, M.J., Ye, C., Tamposky, M.A., 2009. Exercise, sex, menstrual cycle phase, and 17β-estradiol influence metabolism-related genes in human skeletal muscle. Physiological Genomics 40:34–47.

[97] Hoeg, L., Reepstorff, C., Thiele, M., Richter, E.A., Wojtaszewski, J.F., Kiens, B., 2009. Higher intramuscular triacylglycerol in women does not impair insulin sensitivity and proximal insulin signaling. Journal of Applied Physiology 107:824–831.

[98] Garvey, W.T., Maianu, L., Hancock, J.A., Dolch, B.G., Wallace, P., Baron, A.D., 1998. Effects for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. Journal of Clinical Investigation 101:2377–2386.

[99] Garvey, W.T., Maianu, L., Hancock, J.A., Dolch, B.G., Wallace, P., Baron, A.D., 1998. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. Diabetes 41:465–475.

[100] Banks, E.A., Brozinick Jr., J.T., Yaspelkis 3rd, B.B., Kang, H.Y., Ivy, J.L., 1992. Muscle glucose transport, GLUT-4 content, and degree of exercise training in obese Zucker rats. American Journal of Physiology 263:E1010–E1015.

[101] Brozinick Jr., J.T., Delgado Jr., E.G., Yaspelkis 3rd, B.B., Kang, H.Y., Ivy, J.L., 1992. Effects of exercise training on muscle GLUT-4 protein content and translocation in obese Zucker rats. American Journal of Physiology 265:E419–E427.

[102] Brozinick Jr., J.T., Delgado Jr., E.G., Yaspelkis 3rd, B.B., Kang, H.Y., Ivy, J.L., 1994. Glucose uptake and GLUT-4 protein distribution in skeletal muscle of the obese Zucker rat. American Journal of Physiology 267:R236–R243.

[103] Hevener, A.L., Reichart, D., Olefsky, J., 2000. Exercise and thiazolidinedione therapy normalize insulin action in the obese Zucker fatty rat. Diabetes 49:2154–2159.

[104] Dela, F., Ploug, T., Handberg, A., Petersen, L.N., Larsen, J.J., Mikines, K.J., et al., 1994. Physical training increases muscle GLUT4 protein and mRNA in patients with NIDDM. Diabetes 43:862–865.

[105] Rodnick, K.J., Hoilosky, J.O., Monod, C.E., James, D.E., 1990. Effects of exercise training on insulin-regulatable glucose-transporter protein levels in rat skeletal muscle. Diabetes 39:1425–1429.

[106] Lemoine, S., Granier, P., Tiffocco, C., Berthon, P.M., Thieulant, M.L., Carre, F., et al., 2002. Effect of endurance training on oestrogen receptor alpha expression in different rat skeletal muscle type. Acta Physiologica Scandinavica 175:211–217.

[107] Lemoine, S., Granier, P., Tiffocco, C., Berthon, P.M., Rannou-Bekono, F., Thieulant, M.L., et al., 2002. Effect of endurance training on oestrogen receptor alpha transcripts in rat skeletal muscle. Acta Physiologica Scandinavica 174:283–289.

[108] Mora, S., Pessin, J.E., 2000. The MEF2A isoform is required for striated muscle-specific expression of the insulin-responsive GLUT4 glucose transporter. Journal of Biological Chemistry 275:16323–16328.
van Rooij, E., Fiefelt, J., Sutherland, L.B., Thijssen, V.L., Crijns, H.J., Dimajo, M.J., et al., 2010. Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. Circulation Research 106:155 – 165.

Moreno, H., Serrano, A.L., Santalucia, T., Guma, A., Canto, C., Brand, N.J., et al., 2003. Differential regulation of the muscle-specific GLUT4 enhancer in regenerating and adult skeletal muscle. Journal of Biological Chemistry 278: 40557–40564.

Gan, Z., Burkart-Hartmann, E.M., Han, D.H., Finck, B., Leone, T.C., Smith, E.Y., et al., 2011. The nuclear receptor PPARbeta/delta programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes & Development 25: 2619–2630.

Oshel, K.M., Knight, J.B., Cao, K.T., Thai, M.V., Olson, A.L., 2000. Identification of a 30-base pair regulatory element and novel DNA binding protein that regulates the human GLUT4 promoter in transgenic mice. Journal of Biological Chemistry 275:23666–23673.

Smith, J.A., Kohn, T.A., Chetty, A.K., Ojuka, E.O., 2008. CaMK activation during exercise is required for histone hyperacetylation and MEF2A binding at the MEF2 site on the Glut4 gene. American Journal of Physiology Endocrinology and Metabolism 295:E698–E704.

Gong, H., Xie, J., Zhang, N., Yao, L., Zhang, Y., 2011. MEF2A binding to the Glut4 promoter occurs via an AMPKalpha2-dependent mechanism. Medicine & Science in Sports & Exercise 43:1441–1450.

Ordonez, P., Moreno, M., Alonso, A., Llaneza, P., Diaz, F., Gonzalez, C., 2008. 17beta-Estradiol and/or progesterone protect from insulin resistance in STZ-induced diabetic rats. The Journal of Steroid Biochemistry and Molecular Biology 111:287–294.

Galluzzo, P., Rastelli, C., Bulzoni, P., Acconcia, F., Pallottini, V., Marino, M., 2009. 17beta-Estradiol regulates the first steps of skeletal muscle cell differentiation via ER-alpha-mediated signals. American Journal of Cell Physiology 297:C1249–C1262.

Slitt, T.N., Drujan, D., Clarke, B.A., Panaro, F., Timofeyva, Y., Kline, W.O., et al., 2004. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 14:395–403.

Enns, D.L., Iqbal, S., Tiidus, P.M., 2008. Oestrogen receptors mediate oestrogen-induced increases in post-exercise rat skeletal muscle satellite cells. Acta Physiologica (Oxford) 194:81–93.

Enns, D.L., Tiidus, P.M., 2008. Estrogen influences skeletal muscle cell activation and proliferation following downhill running in rats. Journal of Applied Physiology 104:347–353.

Thomas, A., Bunyan, K., Tiidus, P.M., 2010. Oestrogen receptor-alpha activation augments post-exercise myoblast proliferation. Acta Physiologica (Oxford) 198:81–89.

Kamanga-Sollo, E., White, M.E., Hathaway, M.R., Weber, W.J., Dayton, W.R., 2001. Effect of Estradiol-17beta on protein synthesis and degradation rates in fused bovine satellite cell cultures. Domestic Animal Endocrinology 39:54–62.

Lee, Y.R., Park, J., Yu, H.N., Kim, J.S., Youn, H.J., Jung, S.H., 2005. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochemical and Biophysical Research Communications 336:1221–1226.

Noh, E.M., Lee, Y.R., Chay, K.O., Chung, E.Y., Jung, S.H., Kim, J.S., et al., 2011. Estrogen receptor alpha induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells. Molecular Medicine Reports 4:215–219.

Simoncini, T., Hafezi-Moghadam, A., Brazil, D.P., Ley, K., Chin, W.W., Liao, J.K., 2000. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541.

Simoncini, T., Fornari, L., Mannella, P., Varone, G., Caruso, A., Liao, J.K., et al., 2002. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids 67:935 – 939.

Mannella, P., Brinton, R.D., 2006. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: a unified mechanism of estrogen action. Journal of Neuroscience 26:9439–9447.

Ronda, A.C., Vasconsuelo, A., Boland, R., 2010. Extracelular-regulated kinase and p38 mitogen-activated protein kinases are involved in the anti-apoptotic action of 17beta-estradiol in skeletal muscle cells. Journal of Endocrinology 206:235–246.

Ronda, A.C., Buitrago, C., Boland, R., 2010. Role of estrogen receptors, PKC and Src in ERK2 and p38 MAPK signaling triggered by 17beta-estradiol in skeletal muscle cells. The Journal of Steroid Biochemistry and Molecular Biology 122:287–294.

Niu, W., Huang, C., Nawaz, Z., Levy, M., Somwar, R., Li, D., et al., 2003. Maturation of the regulation of Glut4 activity by p38 MAPK during L6 cell myogenesis. Journal of Biological Chemistry 278:17953–17962.

Furtado, L.M., Somwar, R., Sweeney, G., Niu, W., Klip, A., 2002. Activation of the glucose transporter Glut4 by insulin. Biochemistry and Cell Biology 80:569–578.

Sweeney, G., Somwar, R., Ramilal, T., Volchuk, A., Uyama, A., Klip, A., 1999. An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. Journal of Biological Chemistry 274: 10071–10078.

Sorensen, M.B., Rosenfalk, A.M., Hoijagaard, L., Ottesen, B., 2001. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obesity Research 9:622–626.

Leger, B., Derave, W., De Bock, K., Hespel, P., Russell, A.P., 2008. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Research 11:163B–175B.

Tiidus, P.M., 2000. Estrogen and gender effects on muscle damage, inflammation, and oxidative stress. Canadian Journal of Applied Physiology 25:274–287.

Messier, V., Rabasa-Lhoret, R., Barbat-Artigas, S., Elisha, B., Karelis, A.D., Aubertin-Leheudre, M., 2011. Menopause and sarcopenia: a potential role for mTOR. Maturitas 68:331–336.

Chen, Z., Bassford, T., Green, S.B., Cauley, J.A., Jackson, R.D., LaCroix, A.Z., et al., 2005. Postmenopausal hormone therapy and body composition—a substudy of the estrogen plus progesterin trial of the Women's Health Initiative. American Journal of Clinical Nutrition 82:651–656.

Sigila, S., Taaffe, D.R., Cheng, S., Puolakka, J., Toivanen, J., Suominen, H., 2001. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. Clinical Science (London) 101:147–157.

Teixeira, P.J., Going, S.B., Houtkooper, L.B., Metcalfe, L.L., Blew, R.M., Flint-Wagner, H.G., et al., 2003. Resistance training in postmenopausal women with and without hormone therapy. Medicine & Science in Sports & Exercise 35:555–562.

Diei-Conwright, C.M., Spektor, T.M., Rice, J.C., Sattler, F.R., Schroeder, E.T., 2009. Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal women. Journal of Applied Physiology 107:853–858.

Sottiriodou, S., Kyparos, A., Albani, M., Arsos, G., Clarke, M.S., Sidiras, G., et al., 2006. Soleus muscle force following downhill running in ovariectomized rats treated with estrogen. Applied Physiology Nutrition and Metabolism 31:449–459.
[141] Boland, R., Vasconsuelo, A., Milanesi, L., Ronda, A.C., de Boland, A.R., 2008. 17beta-estradiol signaling in skeletal muscle cells and its relationship to apoptosis. Steroids 73:859–863.

[142] Vasconsuelo, A., Milanesi, L., Boland, R., 2008. 17Beta-estradiol abrogates apoptosis in murine skeletal muscle cells through estrogen receptors: role of the phosphatidylinositol 3-kinase/Akt pathway. Journal of Endocrinology 196: 385–397.

[143] Wang, F., He, Q., Sun, Y., Dai, X., Yang, X.P., 2010. Female adult mouse cardiomyocytes are protected against oxidative stress. Hypertension 55: 1172–1178.

[144] McLoughlin, T.J., Smith, S.M., DeLong, A.D., Wang, H., Unterman, T.G., Esser, K.A., 2009. FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. American Journal of Physiology Cell Physiology 297:C548–C555.

[145] Hoeg, L.D., Sjöberg, K.A., Jeppesen, J., Jensen, T.E., Frosg, C., Birke, J.B., et al., 2011. Lipid-induced insulin resistance affects women less than men and is not accompanied by inflammation or impaired proximal insulin signaling. Diabetes 60:64–73.

[146] Corftight, R.N., Koves, T.R., 2000. Sex differences in substrate metabolism and energy homeostasis. Canadian Journal of Applied Physiology 25:288–311.

[147] Amati, F., Dube, J.J., Alvarez-Carnero, E., Edreira, M.M., Chomentowski, P., Cortright, R.N., Koves, T.R., 2000. Sex differences in substrate metabolism and energy homeostasis. Canadian Journal of Applied Physiology 25:288–311.

[148] Maher, A.C., Akhtar, M., Vockley, J., Tarnopolsky, M.A., 2010. Men supplemented with 17beta-estradiol have increased beta-oxidation capacity in skeletal muscle. Physiological Genomics 42:342–347.

[149] Turcotte, L.P., Richter, E.A., Kiens, B., 1992. Increased plasma FFA uptake and oxidation during prolonged exercise in trained vs. untrained humans. American Journal of Physiology 262:E791–E799.

[150] Hamadeh, M.J., Devries, M.C., Tarnopolsky, M.A., 2005. Estrogen supplementation reduces body leucine and carbohydrate oxidation and increases lipid oxidation in men during endurance exercise. Journal of Clinical Endocrinology & Metabolism 90:3592–3599.

[151] Maher, A.C., Akhtar, M., Tarnopolsky, M.A., 2010. Men supplemented with 17beta-estradiol have increased beta-oxidation capacity in skeletal muscle. Physiological Genomics 42:342–347.

[152] D’Eon, T.M., Rogers, N.H., Stancheva, Z.S., Greenberg, A.S., 2008. Estradiol and the estradiol metabolite, 2-hydroxyestradiol, activate AMP-activated protein kinase in C2C12 myotubes. Obesity (Silver Spring) 16:1284–1288.

[153] Mihaylova, M.M., Shaw, R.J., 2011. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nature Cell Biology 13: 1016–1023.

[154] Hardie, D.G., 2011. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes & Development 25:1895–1908.

[155] Kim, J.Y., Jo, K.J., Kim, O.S., Kim, B.J., Kang, D.W., Lee, K.H., et al., 2010. Parenteral 17beta-estradiol decreases fasting blood glucose levels in non-obese mice with short-term overeating. Life Sciences 87:358–366.

[156] Lipovka, Y., Chen, H., Vagner, J., Price, T.J., Tsao, T.S., Konhilas, J.P., 2015. Oestrogen receptors interact with the alpha-catalytic subunit of AMP-activated protein kinase. BioScience Reports 35.

[157] Wellen, K.E., Hotamisligil, G.S., 2005. Inflammation, stress, and diabetes. Journal of Clinical Investigation 115:1111–1119.

[158] Itani, S.I., Ruderman, N.B., Schmieder, F., Boden, G., 2002. Lipid-induced insulin resistance in human muscle is associated with changes in diacetylgluceral, protein kinase C, and IkappaB-alpha. Diabetes 51:2005–2011.

[159] Adams 2nd, J.M., Pratipanawatr, T., Berria, R., Wang, E., DeFronzo, R.A., Sullards, M.C., et al., 2004. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25–31.

[160] Yang, G., Badeanlu, L., Bielawski, J., Roberts, A.J., Hannun, Y.A., Samad, F., 2009. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. American Journal of Physiology Endocrinology and Metabolism 297:E211–E224.

[161] Summers, S.A., 2006. Ceramides in insulin resistance and lipotoxicity. Progress in Lipid Research 45:42–72.

[162] Holland, W.L., Brozniczak, J.T., Wang, L.P., Hawkins, E.D., Sargent, K.M., Liu, Y., et al., 2007. Inhibition of ceramide synthesis ameliorates glucotoxicity–saturated-fat–, and obesity-induced insulin resistance. Cell Metabolism 5:167–179.

[163] Holland, W.L., Knotts, T.A., Chavez, J.A., Wang, L.P., Hoeen, K.L., Summers, S.A., 2007. Lipid mediators of insulin resistance. Nutrition Reviews 65:S39–S46.

[164] Lewis, S.C., Uchiyama, L.F., Nunnari, J., 2016. ER-mitochondria contacts couple mtDNA synthesis with mitochondrial division in human cells. Science 353:aaf5549.

[165] Lai, S., Collins, B.C., Colson, B.A., Kararigas, G., Lowe, D.A., 2016. Estradiol modulates myosin regulatory light chain phosphorylation and contractility in skeletal muscle of female mice. American Journal of Physiology Endocrinology and Metabolism 310:E724–E733.

[166] Collins, B.C., Mader, T.L., Cabelka, C.A., Iligo, M.R., Spangenberg, E.E., Lowe, D.A., 2018 Apr 1. Deletion of estrogen receptor z in skeletal muscle results in impaired contractility in female mice. Journal of Applied Physiology 124(4):980–992. [https://doi.org/10.1152/japplphysiol.00864.2017]. [Epub 2018 Jan 18].

[167] The 2012 hormone therapy position statement of: the North American Menopause Society, Menopause 19, 2012:257–271.

[168] Clemmensen, C., Muller, T.D., Finan, B., Tschop, M.H., DiMarchi, R., 2016. Current and emerging treatment options in diabetes care. Handbook of Experimental Pharmacology 233:437–459.

[169] Vogel, H., Wolf, S., Rabasa, C., Rodriguez-Pacheco, F., Babaei, C.S., Stoher, F., et al., 2016. GLP-1 and estrogen conjugate acts in the supra-mammillary nucleus to reduce food-reward and body weight. Neuropharmacology 110:396–406.

[170] Hewitt, S.C., Korach, K.S., 2018. Estrogen receptors: New directions in the new millennium. Endocrine Reviews.

[171] Ong, C.T., Corces, V.G., 2011. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nature Reviews Genetics 12: 283–293.

[172] Mohammed, H., D’Santos, C., Serandour, A.A., Ali, H.R., Brown, G.D., Atkins, A., et al., 2013. Endogenous purine release reveals GREB1 as a key estrogen receptor regulatory factor. Cell Reports 3:342–349.

[173] Cooke, P.S., Heine, P.A., Taylor, J.A., Lubahn, D.B., 2001. The role of estrogen and estrogen receptor-alpha in male adipose tissue. Molecular and Cellular Endocrinology 178:147–154.

[174] Villablanc, A., Lubahn, D., Shelby, L., Lloyd, K., Barthold, S., 2004. Susceptibility to early atherosclerosis in male mice is mediated by estrogen receptor alpha. Arteriosclerosis Thrombosis and Vascular Biology 24:1065–1061.

[175] Couse, J.F., Curtis, S.W., Washburn, T.F., Eddy, E.M., Schomberg, D.W., Korach, K.S., 1995. Disruption of the mouse oestrogen receptor gene: resulting phenotypes and experimental findings. Biochemical Society Transactions 23:929–935.

[176] Carr, M.C., 2003 Jun. The emergence of the metabolic syndrome with menopause. Journal of Clinical Endocrinology & Metabolism 88(6):2404–2411.